Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Nephrology · Hypertensive Nephrosclerosis

Building Your Care Team and Preparing for Visits

At a Glance

People with hypertensive nephrosclerosis benefit from coordinated kidney care. Bring trends in eGFR, creatinine, UACR, home blood pressure readings, a complete medication list, and family history to nephrology visits, and use clinician-specific plans for medication safety.

Managing hypertensive nephrosclerosis is not a solo journey. Because this condition affects your heart, your blood vessels, and your internal chemistry, your care is most effective when it is managed by a coordinated team [1][2]. Observational studies suggest that patients who receive care from a multidisciplinary team—which may include a physician, nurse, pharmacist, and dietitian—often experience better management of risks compared to those seeing a single doctor [1].

Your Core Care Team

As your condition progresses, your team will likely expand to include several specialists:

  • Nephrologist: The lead specialist for your kidney health who determines your diagnosis, monitors your eGFR and protein levels, and manages complex blood pressure medications [3].
  • Primary Care Provider (PCP): Your central coordinator who manages your overall health, screenings, and standard vaccinations [3].
  • Renal Pharmacist: A critical expert who can help adjust medication doses based on your kidney function and monitor for “nephrotoxins” (drugs that can further damage kidneys, like NSAIDs) [4][5].
  • Renal Dietitian: A specialist who helps you manage your sodium and potassium intake. Note: Blanket potassium restriction is not needed for everyone; your diet should be tailored to your blood levels and medications. [1][6].
  • Social Worker: A professional who can help with practical barriers like medication affordability, transportation, insurance navigation, and health literacy support [2][7].

Preparing for Your First Nephrology Visit

Your first visit is a “deep dive” into your medical history. To get the most out of this appointment, you should arrive with your data organized. Serial values (results over time) are far more useful than a single snapshot [8].

The Essential Data Checklist:

  • Dated Lab History: Bring a record of your eGFR, creatinine, and UACR (protein) results from the last 1–2 years if possible [9][10].
  • Home Blood Pressure Logs: Bring at least two weeks of home readings. Note the time of day, your pulse, and whether you felt any symptoms like dizziness [11][12].
  • Complete Medication List: Include all prescriptions, over-the-counter pain relievers, and herbal supplements [4].
  • Family History: Be ready to discuss any relatives who had kidney failure, early-onset high blood pressure, or needed dialysis [13][14].

When to Consider Genetic Counseling

If you have recent African ancestry or a family history of unexplained kidney disease, your nephrologist may discuss genetic counseling for the APOL1 gene [15][16].

Genetic counseling is more appropriately tied to:

  • Your kidney disease is early-onset, unexplained, or progressing in an atypical way [17][18].
  • You or a family member are considering donating a kidney (to help inform the donor’s long-term risk assessment) [19][20].

A counselor can help you navigate the complex implications of these results, including privacy, insurance implications, and how to communicate findings to family members [21][19]. Testing is generally optional and should be counseling-led.

Collaborative Medication Management

One of the most important roles of your team is managing protective medications like ACE inhibitors or ARBs. These drugs are important for protection but require careful monitoring [22].

  • Creatinine Rises: A rise in creatinine up to about 30% shortly after starting or increasing these medications can sometimes be accepted. However, it still requires prompt clinical review to rule out severe dehydration, NSAID use, or renal artery disease. A rise above that level, severe dizziness, or reduced urine output requires urgent attention [23].
  • Potassium Monitoring: These drugs can raise your potassium levels. While doctors may sometimes use potassium binders or diuretics to manage mild elevations, severe hyperkalemia (dangerously high potassium) is a medical emergency that requires holding the medication and seeking urgent care. Follow your clinician’s specific action thresholds [5][24].
  • Sick-Day Guidance: You must have a clinician-specific written plan detailing which medications (like ACEi, ARBs, diuretics, or SGLT2 inhibitors) should be temporarily held during vomiting, diarrhea, dehydration, prolonged fasting, or surgery, and exactly when and how to restart them [5]. Do not pause medications without guidance.

Common questions in this guide

Which healthcare professionals should care for someone with hypertensive nephrosclerosis?
A nephrologist usually leads kidney care, while a primary care clinician coordinates general health needs. A renal pharmacist, dietitian, and social worker can help with medication safety, diet, and practical barriers; a cardiologist or another specialist may join when needed.
What should I bring to my first nephrology appointment for nephrosclerosis?
Bring dated eGFR, creatinine, and UACR results from the past one to two years if available, plus at least two weeks of home blood pressure readings with the time, pulse, and symptoms. Also bring every prescription, over-the-counter pain reliever, and supplement, along with relevant family history.
Why does my nephrologist need kidney test results from over time?
A series of results shows trends in kidney function and urine protein more clearly than a single test. Changes in eGFR, creatinine, and UACR help the care team assess how the condition is progressing and whether treatment is working.
When might APOL1 genetic counseling be considered?
Your nephrologist may consider counseling if you have recent African ancestry or a family history of unexplained kidney disease, especially when disease begins early, has no clear cause, or progresses atypically. Counseling may also help when you or a relative is considering kidney donation, and testing is generally optional and counseling-led.
What happens if an ACE inhibitor or ARB raises my creatinine or potassium?
A creatinine increase of up to about 30% after starting or increasing one of these medicines may sometimes be accepted, but it still needs prompt clinical review. A larger rise, severe dizziness, reduced urine output, or dangerously high potassium needs urgent medical attention; follow your clinician’s instructions rather than changing the medicine on your own.
What symptoms should prompt a call between nephrology visits?
Contact your care team about new or worsening swelling, changes in urine, severe dizziness, or noticeably reduced urine output. Vomiting, diarrhea, dehydration, or prolonged fasting can also affect medication safety, so ask for and follow a written sick-day plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current eGFR slope, and how frequently should we be monitoring my UACR to ensure my treatment is working?
  2. 2.At what point would you recommend a kidney biopsy to confirm this diagnosis versus treating it as hypertensive nephrosclerosis?
  3. 3.If my potassium levels rise while on my ACE inhibitor or ARB, what specific steps will we take to keep me on these protective medications?
  4. 4.Based on my ancestry and family history, would a referral for APOL1 genetic counseling be appropriate for me or my family members?
  5. 5.How should my other doctors—like my primary care physician or cardiologist—coordinate with you on my blood pressure targets?
  6. 6.What specific symptoms (like swelling or changes in urine) should trigger me to call your office between scheduled visits?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Cardiovascular and Renal Outcomes in an Excellent Chronic Kidney Disease Clinic Compared with an Outpatient Clinic in a Primary Care Setting: A Retrospective Cohort Study.

    Aiumtrakul N, Euswas K, Phichedwanichskul K, et al.

    Kidney diseases (Basel, Switzerland) 2019; (5(3)):144-152 doi:10.1159/000495464.

    PMID: 31259176
  2. 2

    Interdisciplinary care clinics in chronic kidney disease.

    Johns TS, Yee J, Smith-Jules T, et al.

    BMC nephrology 2015; (16()):161 doi:10.1186/s12882-015-0158-6.

    PMID: 26458811
  3. 3

    Chronic kidney disease care models in low- and middle-income countries: a systematic review.

    Stanifer JW, Von Isenburg M, Chertow GM, Anand S

    BMJ global health 2018; (3(2)):e000728 doi:10.1136/bmjgh-2018-000728.

    PMID: 29629191
  4. 4

    Community Pharmacist Training-and-Communication Network and Drug-Related Problems in Patients With CKD: A Multicenter, Cluster-Randomized, Controlled Trial.

    Lalonde L, Quintana-Bárcena P, Lord A, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2017; (70(3)):386-396 doi:10.1053/j.ajkd.2017.05.008.

    PMID: 28663062
  5. 5

    Early diagnosis of chronic kidney disease in patients with diabetes in France: multidisciplinary expert opinion, prevention value and practical recommendations.

    Hannedouche T, Rossignol P, Darmon P, et al.

    Postgraduate medicine 2023; (135(7)):633-645 doi:10.1080/00325481.2023.2256208.

    PMID: 37733403
  6. 6

    Important causes of chronic kidney disease in South Africa.

    Moosa MR, Van der Walt I, Naicker S, Meyers AM

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2015; (105(4)):2681 doi:10.7196/samj.9535.

    PMID: 26294888
  7. 7

    Clinical Effects of Yoga and Meditational Practices on the Holistic Health of Chronic Kidney Disease Patients: A Systematic Review.

    Gautam S, Kiran UV

    Cureus 2024; (16(4)):e57546 doi:10.7759/cureus.57546.

    PMID: 38707181
  8. 8

    The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds.

    Jonsson AJ, Lund SH, Eriksen BO, et al.

    Kidney international 2020; (98(5)):1286-1295 doi:10.1016/j.kint.2020.06.017.

    PMID: 32622831
  9. 9

    Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review.

    Levey AS, Becker C, Inker LA

    JAMA 2015; (313(8)):837-46 doi:10.1001/jama.2015.0602.

    PMID: 25710660
  10. 10

    Biomarkers in chronic kidney disease, from kidney function to kidney damage.

    Lopez-Giacoman S, Madero M

    World journal of nephrology 2015; (4(1)):57-73 doi:10.5527/wjn.v4.i1.57.

    PMID: 25664247
  11. 11

    Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States.

    Foti KE, Wang D, Chang AR, et al.

    Kidney international 2021; (99(3)):686-695 doi:10.1016/j.kint.2020.12.019.

    PMID: 33637204
  12. 12

    Development, Reliability, and Validity of the Home Blood Pressure Monitoring Adherence Scale for Patients with Chronic Kidney Disease.

    Wang Y, Li K, Li H, et al.

    Patient preference and adherence 2020; (14()):1863-1872 doi:10.2147/PPA.S264287.

    PMID: 33116431
  13. 13

    Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology.

    Carriazo S, Vanessa Perez-Gomez M, Ortiz A

    Clinical kidney journal 2020; (13(4)):504-509 doi:10.1093/ckj/sfaa162.

    PMID: 32897275
  14. 14

    Emerging Insights Into Chronic Renal Disease Pathogenesis in Hypertension From Human and Animal Genomic Studies.

    Dhande IS, Braun MC, Doris PA

    Hypertension (Dallas, Tex. : 1979) 2021; (78(6)):1689-1700 doi:10.1161/HYPERTENSIONAHA.121.18112.

    PMID: 34757770
  15. 15

    APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

    Ojo AO, Adu D, Bramham K, et al.

    Kidney international 2025; (108(5)):763-779 doi:10.1016/j.kint.2025.05.017.

    PMID: 40582702
  16. 16

    Clinical Utility of Standardized Genetic Testing in Kidney Transplant Candidate Evaluation.

    Caliskan Y, Elsurer Afsar R, Abu Al Rub F, et al.

    Transplantation direct 2026; (12(5)):e1933 doi:10.1097/TXD.0000000000001933.

    PMID: 42017070
  17. 17

    The Diagnostic Yield of Genomic Sequencing-based Genetic Kidney Disease Testing in Kidney Transplant Candidates: Experience at an Urban US Transplant Center.

    Abu Al Rub F, Elsurer Afsar R, Fleetwood VA, et al.

    Transplantation 2025; (109(7)):1201-1208 doi:10.1097/TP.0000000000005288.

    PMID: 39819994
  18. 18

    Genetic Testing in Adults over 50 Years with Chronic Kidney Disease: Diagnostic Yield and Clinical Implications in a Specialized Kidney Genetics Clinic.

    Schott C, Alajmi M, Bukhari M, et al.

    Genes 2025; (16(4)) doi:10.3390/genes16040408.

    PMID: 40282368
  19. 19

    Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers: A Delphi Consensus Panel Project with Stakeholders.

    McIntosh T, Walsh H, Baldwin K, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2024; (19(4)):494-502 doi:10.2215/CJN.0000000000000397.

    PMID: 38190141
  20. 20

    Practical Considerations for APOL1 Genotyping in the Living Kidney Donor Evaluation.

    Mena-Gutierrez AM, Reeves-Daniel AM, Jay CL, Freedman BI

    Transplantation 2020; (104(1)):27-32 doi:10.1097/TP.0000000000002933.

    PMID: 31449181
  21. 21

    African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study.

    Gordon EJ, Amόrtegui D, Blancas I, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(6)):819-833 doi:10.1053/j.ajkd.2018.07.017.

    PMID: 30360961
  22. 22

    Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.

    Chu CD, Powe NR, Estrella MM, et al.

    Mayo Clinic proceedings 2022; (97(11)):2099-2106 doi:10.1016/j.mayocp.2022.07.010.

    PMID: 36210196
  23. 23

    Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications.

    Cherney DZI, Alicic RZ, Bonaca MP

    Mayo Clinic proceedings 2026; (101(8)):1347-1366 doi:10.1016/j.mayocp.2026.01.010.

    PMID: 42017862
  24. 24

    Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.

    Neuen BL, Oshima M, Agarwal R, et al.

    Circulation 2022; (145(19)):1460-1470 doi:10.1161/CIRCULATIONAHA.121.057736.

    PMID: 35394821

This page is for informational purposes only and does not constitute medical advice. Ask your nephrologist or care team before changing medicines, interpreting lab results, or pursuing genetic testing.

Get notified when new evidence is published on nephrosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.